Literature DB >> 15784725

NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor.

Massimo Vitale1, Mariella Della Chiesa, Simona Carlomagno, Daniela Pende, Maurizio Aricò, Lorenzo Moretta, Alessandro Moretta.   

Abstract

Natural killer (NK) cells were recently shown to play a relevant role in the process of dendritic cell (DC) maturation. This function is exerted either by direct DC stimulation or through killing those DCs that did not properly acquire a mature phenotype. While killing of immature DCs is dependent on the function of the NKp30 triggering receptor, the mechanism by which NK cells induce DC maturation is still unclear. In this study, we show that also the NK-mediated induction of DC maturation is dependent on NKp30. Upon NK/DC interaction, resulting in NKp30 engagement, NK cells produced tumor necrosis factor alpha (TNFalpha) (and interferon gamma [IFNgamma]) that, in turn, promoted DC maturation. Masking of NKp30 with specific monoclonal antibodies (mAbs) strongly reduced maturation of DCs cocultured with NK cells. In addition, supernatant from NK cells stimulated via NKp30 induced DC maturation, and this effect was neutralized by anti-TNFalpha antibodies (Abs). This NKp30 function is controlled by the HLA-specific inhibitory NK receptors. Accordingly, the ability to promote maturation was essentially confined to NK cells expressing the killer immunoglobulin-like receptor-negative (KIR-) NKG2A(dull) phenotype. Finally, the analysis of perforin-deficient NK cells allowed the dissection of the 2 NKp30-mediated NK-cell functions, since NKp30 could induce cytokine-dependent DC maturation in the absence of NK-mediated DC killing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15784725     DOI: 10.1182/blood-2004-10-4035

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  139 in total

1.  Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.

Authors:  Caroline Veuillen; Thérèse Aurran-Schleinitz; Rémy Castellano; Jérôme Rey; Françoise Mallet; Florence Orlanducci; Laurent Pouyet; Sylvaine Just-Landi; Diane Coso; Vadim Ivanov; Xavier Carcopino; Réda Bouabdallah; Yves Collette; Cyril Fauriat; Daniel Olive
Journal:  J Clin Immunol       Date:  2012-02-09       Impact factor: 8.317

2.  Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6.

Authors:  Guoshuai Cao; Jian Wang; Xiaodong Zheng; Haiming Wei; Zhigang Tian; Rui Sun
Journal:  J Biol Chem       Date:  2015-10-15       Impact factor: 5.157

Review 3.  Boosting vaccine efficacy the natural (killer) way.

Authors:  Carolyn E Rydyznski; Stephen N Waggoner
Journal:  Trends Immunol       Date:  2015-08-10       Impact factor: 16.687

Review 4.  Innate lymphocyte and dendritic cell cross-talk: a key factor in the regulation of the immune response.

Authors:  A Reschner; P Hubert; P Delvenne; J Boniver; N Jacobs
Journal:  Clin Exp Immunol       Date:  2008-03-10       Impact factor: 4.330

5.  NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses.

Authors:  Philippe Krebs; Michael J Barnes; Kristin Lampe; Karen Whitley; Keith S Bahjat; Bruce Beutler; Edith Janssen; Kasper Hoebe
Journal:  Blood       Date:  2009-04-30       Impact factor: 22.113

6.  Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation.

Authors:  Francesco Marras; Elena Nicco; Federica Bozzano; Antonio Di Biagio; Chiara Dentone; Emanuele Pontali; Silvia Boni; Maurizio Setti; Giancarlo Orofino; Eugenio Mantia; Valentina Bartolacci; Francesca Bisio; Agostino Riva; Roberto Biassoni; Lorenzo Moretta; Andrea De Maria
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

7.  NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome.

Authors:  Sylvie Rusakiewicz; Gaetane Nocturne; Thierry Lazure; Michaela Semeraro; Caroline Flament; Sophie Caillat-Zucman; Damien Sène; Nicolas Delahaye; Eric Vivier; Kariman Chaba; Vichnou Poirier-Colame; Gunnel Nordmark; Maija-Leena Eloranta; Per Eriksson; Elke Theander; Helena Forsblad-d'Elia; Roald Omdal; Marie Wahren-Herlenius; Roland Jonsson; Lars Rönnblom; Joanne Nititham; Kimberly E Taylor; Christopher J Lessard; Kathy L Moser Sivils; Jacques-Eric Gottenberg; Lindsey A Criswell; Corinne Miceli-Richard; Laurence Zitvogel; Xavier Mariette
Journal:  Sci Transl Med       Date:  2013-07-24       Impact factor: 17.956

Review 8.  The B7 Family Member B7-H6: a New Bane of Tumor.

Authors:  Ying Chen; Jun Mo; Xi Jia; Yang He
Journal:  Pathol Oncol Res       Date:  2017-10-31       Impact factor: 3.201

9.  The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells.

Authors:  Sonja Textor; Felicitas Bossler; Kai-Oliver Henrich; Moritz Gartlgruber; Julia Pollmann; Nathalie Fiegler; Annette Arnold; Frank Westermann; Nina Waldburger; Kai Breuhahn; Sven Golfier; Mathias Witzens-Harig; Adelheid Cerwenka
Journal:  Oncoimmunology       Date:  2016-07-28       Impact factor: 8.110

10.  The depletion of NK cells prevents T cell exhaustion to efficiently control disseminating virus infection.

Authors:  Kevin D Cook; Jason K Whitmire
Journal:  J Immunol       Date:  2012-12-12       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.